Genetic underpinnings of tardive dyskinesia: passing the baton to pharmacogenetics

Papers of special note have been highlighted as either of interest (•) or of considerable interest (••) to readers.

Bibliography

• 1  Casey DE: Tardive dyskinesia. West J. Med.153(5),535–541 (1990).
  Medline CASGoogle Scholar
• 2  Leucht S, Pitschel-Walz G, Abraham D, Kissling W: Efficacy and extrapyramidal side-effects of the new antipsychotics olanzapine, quetiapine, risperidone, and sertindole compared to conventional antipsychotics and placebo. A meta-analysis of randomized controlled trials. Schizophr. Res.35(1),51–68 (1999).
  Medline CASGoogle Scholar
• 3  Geddes J, Freemantle N, Harrison P, Bebbington P: Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ321(7273),1371–1376 (2000).
  Medline CASGoogle Scholar
• 4  Davis JM, Chen N, Glick ID: A meta-analysis of the efficacy of second-generation antipsychotics. Arch. Gen. Psychiatry60(6),553–564 (2003).
  Medline CASGoogle Scholar
• 5  Lieberman JA, Stroup TS, McEvoy JP et al.: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N. Engl. J. Med.353(12),1209–1223 (2005).
  Medline CASGoogle Scholar
• 6  Jones PB, Barnes TR, Davies L et al.: Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch. Gen. Psychiatry63(10),1079–1087 (2006).
  Medline CASGoogle Scholar
• 7  Rosenheck RA, Leslie DL; CATIE Study Investigators et al.: Cost-effectiveness of second-generation antipsychotics and perphenazine in a randomized trial of treatment for chronic schizophrenia. Am. J. Psychiatry163(12),2080–2089 (2006).
  MedlineGoogle Scholar
• 8  Davies LM, Lewis S; CUtLASS team et al.: Cost-effectiveness of first- v. second-generation antipsychotic drugs: results from a randomised controlled trial in schizophrenia responding poorly to previous therapy. Br. J. Psychiatry191,14–22 (2007).
  Medline CASGoogle Scholar
• 9  Hoenberg K, Taylor N, Goetz Welch J: Antipsychotics: Analysis of disease Markets and Emerging Agents. Decision Resources, Inc., MA, USA (2006).
  Google Scholar
• 10  Krantz JC: Pharmacogenetics: heredity and response to drugs. The Quarterly Review of Biology. Kalow W (Ed.). The University of Chicago Press, IL, USA, 39(4),390 (1964).
  Google Scholar
• 11  Dash S, Dash RJ: Spectrum of haemolytic anaemias in Punjab, North India. Trop. Geogr. Med.32(4),312–316 (1980).
  Medline CASGoogle Scholar
• 12  Sidrak W, Fox E, Polycarpe D et al.: Dissimilar glucose-6-phosphate dehydrogenase (G-6-PD) deficiency in the Afars and the Somalis of Djibouti. Med. Trop. (Mars).51(2),211–214 (1991).
  Medline CASGoogle Scholar
• 13  Wajcman H, Galactéros F: Glucose 6-phosphate dehydrogenase deficiency: a protection against malaria and a risk for hemolytic accidents. C. R. Biol.327(8),711–720 (2004).
  Medline CASGoogle Scholar
• 14  Basile VS, Masellis M, Potkin SG, Kennedy JL: Pharmacogenomics in schizophrenia: the quest for individualized therapy. Hum. Mol. Genet.11,2517–2530 (2002).•• Reviews the progress in the field of tardive dyskinesia (TD) genetics.
  Medline CASGoogle Scholar
• 15  Bolonna AA, Arranz MJ, Mancama D, Kerwin RW: Pharmacogenomics – can genetics help in the care of psychiatric patients? Int. Rev. Psychiatry16(4),311–319 (2004).•• Reviews the progress in the field of TD genetics.
  Medline CASGoogle Scholar
• 16  Lerer B, Segman RH: Pharmacogenetics of antipsychotic therapy: pivotal research issues and the prospects for clinical implementation. Dialogues Clin. Neurosci.8(1),85–94 (2006).•• Reviews the progress in the field of TD genetics.
  MedlineGoogle Scholar
• 17  Arranz MJ, de Leon J: Pharmacogenetics and pharmacogenomics of schizophrenia: a review of last decade of research. Mol. Psychiatry12(8),707–747 (2007).•• Reviews the progress in the field of TD genetics.
  Medline CASGoogle Scholar
• 18  Maier W, Zobel A: Contribution of allelic variations to the phenotype of response to antidepressants and antipsychotics. Eur. Arch. Psychiatry Clin. Neurosci.258(Suppl. 1),12–20 (2008).•• Reviews the progress in the field of TD genetics.
  MedlineGoogle Scholar
• 19  Tepper SJ, Haas JF: Prevelance of tardive dyskinesia. J. Clin. Psychiatry40,508–516 (1979).
  Medline CASGoogle Scholar
• 20  Geralch J, Casey DE: Tardive dyskinesia. Acta Psychiatr. Scand.77,369–378 (1988).
  MedlineGoogle Scholar
• 21  Yassa R, Jeste DV: Gender differences in tardive dyskinesia: a critical review of the literature. Schizophr. Bull.18(4),701–715 (1992).
  Medline CASGoogle Scholar
• 22  Glazer WM, Morgenstern H, Doucette JT: Predicting the long-term risk of tardive dyskinesia in outpatients maintained on neuroleptic medications. J. Clin. Psychiatry54(4),133–139 (1993).
  Medline CASGoogle Scholar
• 23  Morgenstern H, Glazer WM: Identifying risk factors for tardive dyskinesia among long-term outpatients maintained with neuroleptic medications. Results of the Yale Tardive Dyskinesia Study. Arch. Gen. Psychiatry50(9),723–733 (1993).
  Medline CASGoogle Scholar
• 24  Glazer WM, Morgenstern H, Doucette JT: Race and tardive dyskinesia among outpatients at a CMHC. Hosp. Community Psychiatry45(1),38–42 (1994).
  Medline CASGoogle Scholar
• 25  Holden TJ: Tardive dyskinesia in long-term hospitalised Zulu psychiatric patients. A prevalence study. S. Afr. Med. J.71(2),88–90 (1987).
  Medline CASGoogle Scholar
• 26  Wonodi I, Adami HM, Cassady SL, Sherr JD, Avila MT, Thaker GK: Ethnicity and the course of tardive dyskinesia in outpatients presenting to the motor disorders clinic at the Maryland psychiatric research center. J. Clin. Psychopharmacol.24(6),592–598 (2004).
  MedlineGoogle Scholar
• 27  Wonodi I, Reeves G, Carmichael D et al.: Tardive dyskinesia in children treated with atypical antipsychotic medications. Mov. Disord.22(12),1777–1782 (2007).
  MedlineGoogle Scholar
• 28  Tarsy D, Baldessarini RJ: Epidemiology of tardive dyskinesia: is risk declining with modern antipsychotics? Mov. Disord.21(5),589–598 (2006).
  MedlineGoogle Scholar
• 29  Sigwald J, Bouttier D, Courvoisier S: Neurological complications of neuroleptic medication. Rev. Neurol. (Paris).100,553–595 (1959).
  Medline CASGoogle Scholar
• 30  Druckman R, Seelinger D, Thulin B: Chronic involuntary movements induced by phenothiazines. J. Nerv. Ment. Dis.135,69–76 (1962).
  Medline CASGoogle Scholar
• 31  Miller DD, McEvoy JP, Davis SM et al.: Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr. Res.80(1),33–43 (2005).
  MedlineGoogle Scholar
• 32  Jeste DV, Lacro JP, Palmer B, Rockwell E, Harris MJ, Caligiuri MP: Incidence of tardive dyskinesia in early stages of low-dose treatment with typical neuroleptics in older patients. Am. J. Psychiatry156(2),309–311 (1999).
  Medline CASGoogle Scholar
• 33  van Os J, Walsh E, van Horn E, Tattan T, Bale R, Thompson SG: Tardive dyskinesia in psychosis: are women really more at risk? UK700 Group. Acta Psychiatr. Scand.99(4),288–293 (1999).
  MedlineGoogle Scholar
• 34  Myers DE, Schooler NR, Zullo TG, Levin H: A retrospective study of the effects of edentulism on the severity rating of tardive dyskinesia. J. Prosthet. Dent.69(6),578–581 (1993).
  Medline CASGoogle Scholar
• 35  Osman A, Marghalani M, Turkistani IY, Al-Swaf M, Bin Sadiq B: Neuroleptic-induced tardive dyskinesia among Arab psychotic patients. East. Mediterr. Health J.13(3),625–632 (2007).
  Medline CASGoogle Scholar
• 36  Swartz JR, Burgoyne K, Smith M, Gadasally R, Ananth J, Ananth K: Tardive dyskinesia and ethnicity: review of the literature. Ann. Clin. Psychiatry9(1),53–59 (1997).
  Medline CASGoogle Scholar
• 37  Doongaji DR, Jeste DV, Jape NM et al.: Tardive dyskinesia in India: a prevalence study. J. Clin. Psychopharmacol.2(5),341–344 (1982).
  Medline CASGoogle Scholar
• 38  Pandurangi AK, Channabasavanna HM, Ananth J: Dyskinesia in an Indian mental hospital. Indian J. Psychiatry20,339–342 (1978).
  Google Scholar
• 39  Datta S, Subhalaxmi TP, Jeyseelan L, Kuruvilla K: Risk factor for tardive dyskinesia. Indian J. Psychiatry36(1),22–24 (1994).
  Medline CASGoogle Scholar
• 40  Bhatia T, Sabeeha MR, Shriharsh V et al.: Clinical and familial correlates of tardive dyskinesia in India and Israel. J. Postgrad. Med.50(3),167–172 (2004).
  Medline CASGoogle Scholar
• 41  O’Callaghan E, Larkin C, Kinsella A, Waddington JL: Obstetric complications, the putative familial-sporadic distinction, and tardive dyskinesia in schizophrenia. Br. J. Psychiatry157,578–584 (1990).
  MedlineGoogle Scholar
• 42  Yassa R, Ananth J: Familial tardive dyskinesia. Am. J. Psychiatry138(12),1618–1619 (1981).
  Medline CASGoogle Scholar
• 43  Muller DJ, Schulze TG, Knapp M et al.: Familial occurrence of tardive dyskinesia. Acta Psychiatr. Scand.104(5),375–379 (2001).
  Medline CASGoogle Scholar
• 44  Segman RH, Heresco-Levy U, Finkel B et al.: Association between the serotonin 2A receptor gene and tardive dyskinesia in chronic schizophrenia. Mol. Psychiatry6,225–229 (2001).
  Medline CASGoogle Scholar
• 45  Casey DE: Dopamine D1 (SCH 23390) and D2 (haloperidol) antagonists in drug-naive monkeys. Psychopharmacology (Berl.)107,18–22 (1992).
  Medline CASGoogle Scholar
• 46  Rosengarten H, Schweitzer JW, Friedhoff AJ: Possible genetic factors underlying the pathophysiology of tardive dyskinesia. Pharmacol. Biochem. Behav.49,663–667 (1994).
  Medline CASGoogle Scholar
• 47  Tamminga CA, Dale JM, Goodman L, Kaneda H, Kaneda N: Neuroleptic-induced vacuous chewing movements as an animal model of tardive dyskinesia: a study in three rat strains. Psychopharmacology (Berl.)102,474–478 (1990).
  Medline CASGoogle Scholar
• 48  Tanaka E, Hisawa S: Clinically significant pharmacokinetic drug interactions with psychoactive drugs: antidepressants and antipsychotics and the cytochrome P450 system. J. Clin. Pharm. Ther.24,7–16 (1999).
  Medline CASGoogle Scholar
• 49  Otani K, Aoshima T: Pharmacogenetics of classical and new antipsychotic drugs. Ther. Drug Monit.22,118–121 (2000).
  Medline CASGoogle Scholar
• 50  Shimada T, Yamazaki H, Mimura M, Inui Y, Gungerich FP: Interindividual variations in human liver cytochrome P450 enzymes involved in the oxidation of drugs, carcinogens and toxic chemicals: studies with liver microsomes of 30 Japanese and 30 Caucasians. J. Pharmacol. Ther.270,414–423 (1994).
  Medline CASGoogle Scholar
• 51  Nebert DW, Dieter MZ: The evolution of drug metabolism. Pharmacology61,124–135 (2000).
  Medline CASGoogle Scholar
• 52  Bradford LD, Kirlin WG: Polymorphism of CYP2D6 in Black populations: implications for psychopharmacology. Int. J. Neuropsychopharmacol.1,173–185 (1998).
  MedlineGoogle Scholar
• 53  Bertilsson L, Dahl ML, Dalen P, Al-Shurbaji A: Molecular genetics of CYP2D6: clinical relevance with focus on psychotropic drugs. Br. J. Clin. Pharmacol.53,111–122 (2002).
  Medline CASGoogle Scholar
• 54  Schelkunov EL: Adrenergic effect of chronic administration of neuroleptics. Nature214,1210–1212 (1967).
  Medline CASGoogle Scholar
• 55  Klawans HL, Rubovits R: An experimental model of tardive dyskinesia. J. Neural Transm.33,235–246 (1972).
  MedlineGoogle Scholar
• 56  Tarsy D, Baldessarini RJ: Pharmacologically induced behavioral supersensitivity to apomorphine. Nature245,262–263 (1973).
  Google Scholar
• 57  Christensen AV, Fjalland B, Nielsen IM: On the supersensitivity of dopamine receptors induced by neuroleptics. Psychopharmacology48,1–6 (1976).
  Medline CASGoogle Scholar
• 58  Clow A, Jenner P, Marsden CD: Changes in dopamine-mediated behaviour during one year’s neuroleptic administration. Eur. J. Pharmacol.57,365–375 (1979).
  Medline CASGoogle Scholar
• 59  Casey DE: Tardive dyskinesia-animal models. Psychopharmacol. Bull.20,376–379 (1984).
  Medline CASGoogle Scholar
• 60  Casey DE: Pathophysiology of antipsychotic drug-induced movement disorders. J. Clin. Psychiatry65(Suppl. 9),25–28 (2004).
  Medline CASGoogle Scholar
• 61  Burt DR, Creese I, Snyder SH: Antischizophrenic drugs: chronic treatment elevates dopamine receptor binding in brain. Science196(4287),326–328 (1977).
  Medline CASGoogle Scholar
• 62  Waddington JL, Cross AJ, Gamble SJ, Bourne RC: Spontaneous orofacial dyskinesia and dopaminergic function in rats after 6 months of neuroleptic treatment. Science220,530–532 (1983).
  Medline CASGoogle Scholar
• 63  Wolfe ME, Monsnaim AD: Tardive dyskinesia: Biological mechanisms and clinical aspects. American Psychiatric Press, Washington DC, USA (1988).
  Google Scholar
• 64  Waldmeier PC, Delini-Stula AA: Serotonin – dopamine interactions in the nigrostriatal system. Eur. J. Pharmacol.55,363–373 (1979).
  Medline CASGoogle Scholar
• 65  Balsara JJ, Jadhav JH, Chandorkar AG: Effect of drugs influencing central serotonergic mechanisms on haloperidol-induced catalepsy. Psychopharmacology (Berl.)62,67–69 (1979).
  Medline CASGoogle Scholar
• 66  Kinon BJ, Lieberman JA: Mechanisms of action of atypical antipsychotic drugs: a critical analysis. Psychopharmacology (Berl.)124,2–34 (1996).
  Medline CASGoogle Scholar
• 67  Kulikov AV, Kozlachkova EY, Popova NK: Activity of tryptophan hydroxylase in brain of hereditary predisposed to catalepsy rats. Pharmacol. Biochem. Behav.43,999–1003 (1992).
  Medline CASGoogle Scholar
• 68  Kulikov AV, Avgustinovich DF, Kolpakov VG, Maslova GB, Popova NK: 5-HT2A serotonin receptors in the brain of rats and mice hereditarily predisposed to catalepsy. Pharmacol. Biochem. Behav.50,383–387 (1995).
  Medline CASGoogle Scholar
• 69  Kulikov AV, Kozlachkova EY, Kudryavtseva NN, Popova NK: Correlation between tryptophan hydroxylase activity in the brain and predisposition to pinch-induced catalepsy in mice. Pharmacol. Biochem. Behav.50,431–435 (1995).
  Medline CASGoogle Scholar
• 70  Popova NK, Kulikov AV, Kolpakov VG, Barykina NN, Alekhina TA: Changes in the serotonin system of the brains of rats genetically predisposed to catalepsy. Zh. Vyssh. Nerv. Deiat. Im. I P Pavlova35,742–746 (1985).
  Medline CASGoogle Scholar
• 71  Kulikov AV, Kolpakov VG, Maslova GB, Kozintsev I, Popova NK: Effect of selective 5-HT1A agonists and 5-HT2 antagonists on inherited catalepsy in rats. Psychopharmacology (Berl.)114,172–174 (1994).
  Medline CASGoogle Scholar
• 72  Fibiger HC, Lloyd KG: Neurobiological substrates of tardive dyskinesia: the GABA hypothesis. Trends Neurosci.7,462–464 (1984).
  CASGoogle Scholar
• 73  Gunne LM, Bachus SE, Gale K: Oral movements induced by interference with nigral GABA neurotransmission: relationship to tardive dyskinesias. Exp. Neurol.100(3),459–469 (1988).
  Medline CASGoogle Scholar
• 74  Thaker GK, Tamminga CA, Alphs LA, Lafferman J, Ferraro TN, Hare TA: Brain γ-aminobutyric acid abnormality in tardive dyskinesia. Arch. Gen. Psychiatry44,522–529 (1987).
  Medline CASGoogle Scholar
• 75  Andreassen OA, Jorgensen HA: Neurotoxicity associated with neuroleptic-induced oral dyskinesias in rats. Implications for tardive dyskinesia? Prog. Neurobiol.61(5),525–541 (2000).
  Medline CASGoogle Scholar
• 76  McGeer EG, McGeer PL: Duplication of biochemical changes of Huntington’s chorea by intrastriatal injections of glutamic and kainic acids. Nature263,517–519 (1976).
  Medline CASGoogle Scholar
• 77  Andreassen OA, Jorgensen HA: GM1 ganglioside attenuates the development of vacuous chewing movements induced by long-term haloperidol treatment of rats. Psychopharmacology (Berl.)116,517–522 (1994).
  Medline CASGoogle Scholar
• 78  Andreassen OA, Aamo TO, Joorgensen HA: Inhibition by memantine of the development of persistent oral dyskinesias induced by long-term haloperidol treatment of rats. Br. J. Pharmacol.9,751–757 (1996).
  Google Scholar
• 79  Meshul CK, Stallbaumer RK, Taylor B, Janowsky A: Haloperidol-induced morphological changes in striatum are associated with glutamate synapses. Brain Res.648,181–195 (1994).
  Medline CASGoogle Scholar
• 80  Yamamoto BK, Davy S: Dopaminergic modulation of glutamate release in striatum as measured by microdialysis. J. Neurochem.58,1736–1742 (1992).
  Medline CASGoogle Scholar
• 81  Liou YJ, Wang YC, Chen JY et al.: Association analysis of polymorphisms in the N-methyl-D-aspartate (NMDA) receptor subunit 2B (GRIN2B) gene and tardive dyskinesia in schizophrenia. Psychiatry Res.153(3),271–275 (2007).
  Medline CASGoogle Scholar
• 82  Cadet JL, Lohr JB: Possible involvement of free radicals in neuroleptic-induced movement disorders. Evidence from treatment of tardive dyskinesia with vitamin E. Ann. NY Acad. Sci.570,176–185 (1989).
  Medline CASGoogle Scholar
• 83  Elkashef AM, Wyatt RJ: Tardive dyskinesia: possible involvement of free radicals and treatment with vitamin E. Schizophr. Bull.25,731–740 (1999).
  Medline CASGoogle Scholar
• 84  Cadet JL, Perumal AS: Chronic treatment with prolixin causes oxidative stress in rat brain. Biol. Psychiatry28,738–740 (1990).
  Medline CASGoogle Scholar
• 85  Benzi G, Moretti A: Age- and peroxidative stress-related modifications of the cerebral enzymatic activities linked to mitochondria and the glutathione system. Free Radic. Biol. Med.19,77–101 (1995).
  Medline CASGoogle Scholar
• 86  Butterfield DA, Castegna A, Drake J, Scapagnini G, Calabrese V: Vitamin E and neurodegenerative disorders associated with oxidative stress. Nutr. Neurosci.5,229–239 (2002).
  Medline CASGoogle Scholar
• 87  Phillips KA, van Bebber SL: Measuring the value of pharmacogenomics. Nat. Rev. Drug Discov.4(6),500–509 (2005).
  Google Scholar
• 88  Remington G: Understanding antipsychotic ”atypicality“: a clinical and pharmacological moving target. J. Psychiatry Neurosci.28,275–284 (2003).
  MedlineGoogle Scholar
• 89  Sanger DJ: The search for novel antipsychotics: pharmacological and molecular targets. Expert Opin. Ther. Targets8,631–641 (2004).
  Medline CASGoogle Scholar
• 90  Chen CH, Wei FC, Koong FJ, Hsiao KJ: Association of TaqI A polymorphism of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Biol. Psychiatry.41(7),827–829 (1997).
  Medline CASGoogle Scholar
• 91  Liou YJ, Lai IC, Liao DL et al.: The human dopamine receptor D2 (DRD2) gene is associated with tardive dyskinesia in patients with schizophrenia. Schizophr. Res.86(1–3),323–325 (2006).
  MedlineGoogle Scholar
• 92  Zai CC, De Luca V, Hwang RW et al.: Meta-analysis of two dopamine D2 receptor gene polymorphisms with tardive dyskinesia in schizophrenia patients. Mol. Psychiatry12(9),794–795 (2007).
  Medline CASGoogle Scholar
• 93  Bakker PR, van Harten PN, van Os J: Antipsychotic-induced tardive dyskinesia and polymorphic variations in COMT, DRD2, CYP1A2 and MnSOD genes: a meta-analysis of pharmacogenetic interactions. Mol. Psychiatry13(5),544–556 (2008).
  Medline CASGoogle Scholar
• 94  Sokoloff P, Diaz J, Le Foll B et al.: The dopamine D3 receptor: a therapeutic target for the treatment of neuropsychiatric disorders. CNS Neurol. Disord. Drug Targets5(1),25–43 (2006).
  Medline CASGoogle Scholar
• 95  Landwehrmeyer B, Mengod G, Palacios JM: Dopamine D3 receptor mRNA and binding sites in human brain. Brain Res. Mol. Brain Res.18(1–2),187–192 (1993).
  Medline CASGoogle Scholar
• 96  Sokoloff P, Giros B, Martres MP, Bouthenet ML, Schwartz JC: Molecular cloning and characterization of a novel dopamine receptor (D3) as a target for neuroleptics. Nature347,146–151 (1990).
  Medline CASGoogle Scholar
• 97  Gurevich EV, Bordelon Y, Shapiro RM, Arnold SE, Gur RE, Joyce JN: Mesolimbic dopamine D3 receptors and use of antipsychotics in patients with schizophrenia. A postmortem study. Arch. Gen. Psychiatry54,225–232 (1997).
  Medline CASGoogle Scholar
• 98  Meador-Woodruff JH, Haroutunian V, Powchik P, Davidson M, Davis KL, Watson SJ: Dopamine receptor transcript expression in striatum and prefrontal and occipital cortex. Focal abnormalities in orbitofrontal cortex in schizophrenia. Arch. Gen. Psychiatry54,1089–1095 (1997).
  Medline CASGoogle Scholar
• 99  Kling-Peterson T, Ljung E, Svensson K: Effects on locomotor activity after local application of D3 preferring compounds in discrete areas of the rat brain. J. Neural Transm.102,209–220 (1995).
  Google Scholar
• 100  Accili D, Fishburn CS, Drago J et al.: A targeted mutation of the D3 dopamine receptor gene is associated with hyperactivity in mice. Proc. Natl Acad. Sci. USA93(5),1945–1949 (1996).
  Medline CASGoogle Scholar
• 101  Fink-Jensen A, Nielsen EB, Hansen L, Scheideler MA: Behavioral and neurochemical effects of the preferential dopamine D3 receptor agonist cis-8-OH-PBZI. Eur. J. Pharmacol.342(2–3),153–161 (1998).
  Medline CASGoogle Scholar
• 102  Lundstrom K, Turpin MP: Proposed schizophrenia-related gene polymorphism: expression of the Ser9Gly mutant human dopamine D3 receptor with the Semliki Forest virus system. Biochem. Biophys. Res. Commun.225(3),1068–1072 (1996).
  Medline CASGoogle Scholar
• 103  Chong SA, Tan EC, Tan CH, Mythily, Chan YH: Polymorphisms of dopamine receptors and tardive dyskinesia among Chinese patients with schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet.116,51–54 (2003).
  Google Scholar
• 104  Murthy JN, Laev H, Karpiak S et al.: Enzymes of oxyradical metabolism after haloperidol treatment in rat. Abstr. – Soc. Neurosci.15,139 (1989).
  Google Scholar
• 105  Rosenblum JS, Gilula NB, Lerner RA: On signal sequence polymorphisms and diseases of distribution. Proc. Natl Acad. Sci. USA93(9),4471–4473 (1996).
  Medline CASGoogle Scholar
• 106  Shimoda-Matsubayashi S, Matsumine H, Kobayashi T, Nakagawa-Hattori Y, Shimizu Y, Mizuno Y: Structural dimorphism in the mitochondrial targeting sequence in the human manganese superoxide dismutase gene. A predictive evidence for conformational change to influence mitochondrial transport and a study of allelic association in Parkinson’s disease. Biochem. Biophys. Res. Commun.226(2),561–565 (1996); Erratum in: Biochem. Biophys. Res. Commun.229(1),361 (1996).
  Medline CASGoogle Scholar
• 107  Hitzeroth A, Niehaus DJ, Koen L, Botes WC, Deleuze JF, Warnich L: Association between the MnSOD Ala-9Val polymorphism and development of schizophrenia and abnormal involuntary movements in the Xhosa population. Prog. Neuropsychopharmacol. Biol. Psychiatry.31(3),664–672 (2007).
  Medline CASGoogle Scholar
• 108  Hori H, Ohmori O, Shinkai T et al.: Manganese superoxide dismutase gene polymorphism and schizophrenia: relation to tardive dyskinesia. Neuropsychopharmacology23(2),170–177 (2000).
  Medline CASGoogle Scholar
• 109  Galecki P, Pietras T, Szemraj J: Manganese superoxide dismutase gene (MnSOD) polimorphism in schizophrenics with tardive dyskinesia from central Poland. Psychiatr. Pol.40(5),937–948 (2006).
  MedlineGoogle Scholar
• 110  Elson JL, Turnbull DM, Howell N: Comparative genomics and the evolution of human mitochondrial DNA: assessing the effects of selection. Am. J. Hum. Genet.74(2),229–238 (2004).
  Medline CASGoogle Scholar
• 111  Rand DM, Kann LM: Excess amino acid polymorphism in mitochondrial DNA: contrasts among genes from Drosophila, mice, and humans. Mol. Biol. Evol.13,735–748 (1996).
  Medline CASGoogle Scholar
• 112  Hasegawa M, Cao Y, Yang Z: Preponderance of slightly deleterious polymorphism in mitochondrial DNA: nonsynonymous/synonymous rate ratio is much higher within species than between species. Mol. Biol. Evol.15,1499–1505 (1998).
  Medline CASGoogle Scholar
• 113  Moilanen JS, Majamaa K: Phylogenetic network and physicochemical properties of nonsynonymous mutations in the protein-coding genes of human mitochondrial DNA. Mol. Biol. Evol.20,1195–1210 (2003).
  Medline CASGoogle Scholar
• 114  Moilanen JS, Finnilä S, Majamaa K: Lineage-specific selection in human mtDNA: lack of polymorphisms in a segment of MTND5 gene in haplogroup J. Mol. Biol. Evol.20,2132–2142 (2003).
  Google Scholar
• 115  Kovoor A, Seyffarth P, Ebert J et al.: D2 dopamine receptors colocalize regulator of G-protein signaling 9-2 (RGS9-2) via the RGS9 DEP domain, and RGS9 knock-out mice develop dyskinesias associated with dopamine pathways. J. Neurosci.25(8),2157–2165 (2005).
  Medline CASGoogle Scholar
• 116  Liou YJ, Chen ML, Wang YC et al.: Analysis of genetic variations in the RGS9 gene and antipsychotic-induced tardive dyskinesia in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet. (2008) (Epub ahead of print).
  MedlineGoogle Scholar
• 117  Segman RH, Heresco-Levy U, Yakir A et al.: Interactive effect of cytochrome P450 17α-hydroxylase and dopamine D3 receptor gene polymorphisms on abnormal involuntary movements in chronic schizophrenia. Biol. Psychiatry51(3),261–263 (2002).
  Medline CASGoogle Scholar
• 118  Zhang ZJ, Zhang XB, Hou G, Yao H, Reynolds GP: Interaction between polymorphisms of the dopamine D3 receptor and manganese superoxide dismutase genes in susceptibility to tardive dyskinesia. Psychiatr. Genet.13(3),187–192 (2003).
  MedlineGoogle Scholar
• 119  Burdick KE, Kamiya A, Hodgkinson CA et al.: Elucidating the relationship between DISC1, NDEL1, and NDE1 and the risk for schizophrenia: evidence of epistasis and competitive binding. Hum. Mol. Genet.17(16),2462–2473 (2008).
  Medline CASGoogle Scholar
• 120  Pickard BS, Christoforou A, Thomson PA et al.: Interacting haplotypes at the NPAS3 locus alter risk of schizophrenia and bipolar disorder. Mol. Psychiatry (2008) (Epub ahead of print).
  MedlineGoogle Scholar
• 121  Hänninen K, Katila H, Saarela M et al.: Interleukin-1 β gene polymorphism and its interactions with neuregulin-1 gene polymorphism are associated with schizophrenia. Eur. Arch. Psychiatry Clin. Neurosci.258(1),10–15 (2008).
  MedlineGoogle Scholar
• 122  Alfimova MV, Golimbet VE, Gritsenko IK et al.: Interaction of dopamine system genes and cognitive functions in patients with schizophrenia and their relatives and in healthy subjects from the general population. Neurosci. Behav. Physiol.37(7),643–650 (2007).
  Medline CASGoogle Scholar
• 123  Morris DW, Murphy K, Kenny N et al.: Dysbindin (DTNBP1) and the biogenesis of lysosome-related organelles complex 1 (BLOC-1): main and epistatic gene effects are potential contributors to schizophrenia susceptibility. Biol. Psychiatry63(1),24–31 (2008).
  Medline CASGoogle Scholar
• 124  Benzel I, Bansal A, Browning BL et al.: Interactions among genes in the ErbB-Neuregulin signalling network are associated with increased susceptibility to schizophrenia. Behav. Brain Funct.3,31 (2007).
  MedlineGoogle Scholar
• 125  Straub RE, Lipska BK, Egan MF et al.: Allelic variation in GAD1 (GAD67) is associated with schizophrenia and influences cortical function and gene expression. Mol. Psychiatry12(9),854–869 (2007).
  Medline CASGoogle Scholar
• 126  Lachman HM, Pedrosa E, Nolan KA, Glass M, Ye K, Saito T: Analysis of polymorphisms in AT-rich domains of neuregulin 1 gene in schizophrenia. Am. J. Med. Genet. B Neuropsychiatr. Genet.141B(1),102–109 (2006).
  Medline CASGoogle Scholar
• 127  Ikeda M, Iwata N, Kitajima T et al.: Positive association of the serotonin 5-HT7 receptor gene with schizophrenia in a Japanese population. Neuropsychopharmacology31(4),866–871 (2006).
  Medline CASGoogle Scholar
• 128  Gysin R, Kraftsik R, Sandell J et al.: Impaired glutathione synthesis in schizophrenia: convergent genetic and functional evidence. Proc. Natl Acad. Sci. USA104(42),16621–16626 (2007).
  Medline CASGoogle Scholar
• 129  Yamada K, Gerber DJ, Iwayama Y et al.: Genetic analysis of the calcineurin pathway identifies members of the EGR gene family, specifically EGR3, as potential susceptibility candidates in schizophrenia. Proc. Natl Acad. Sci. USA104(8),2815–2820 (2007).
  Medline CASGoogle Scholar
• 130  Buckholtz JW, Meyer-Lindenberg A, Honea RA et al.: Allelic variation inRGS4 impacts functional and structural connectivity in the human brain. J. Neurosci.27(7),1584–1593 (2007).
  Medline CASGoogle Scholar
• 131  Talkowski ME, Kirov G, Bamne M et al.: A network of dopaminergic gene variations implicated as risk factors for schizophrenia. Hum. Mol. Genet.17(5),747–758 (2008).
  Medline CASGoogle Scholar
• 132  Zhang Z, Zhang X, Hou G, Sha W, Reynolds GP: The increased activity of plasma manganese superoxide dismutase in tardive dyskinesia is unrelated to the Ala-9Val polymorphism. J. Psychiatr. Res.36(5),317–324 (2002).
  MedlineGoogle Scholar
• 133  Tan YL, Zhou DF, Zhang XY: Decreased plasma brain-derived neurotrophic factor levels in schizophrenic patients with tardive dyskinesia: association with dyskinetic movements. Schizophr. Res.74(2–3),263–270 (2005).
  MedlineGoogle Scholar
• 134  Srivastava V, Varma PG, Prasad S et al.: Genetic susceptibility to tardive dyskinesia among schizophrenia subjects: IV. Role of dopaminergic pathway gene polymorphisms. Pharmacogenet. Genomics16(2),111–117 (2006).
  Medline CASGoogle Scholar
• 135  Weinshilboum RM, Raymond FA: Inheritance of low erythrocyte catechol-O-methyltransferase activity in man. Am. J. Hum. Genet.29,125–135 (1977).
  Medline CASGoogle Scholar
• 136  Inada T, Koga M, Ishiguro H et al.: Pathway-based association analysis of genome-wide screening data suggest that genes associated with the γ-aminobutyric acid receptor signaling pathway are involved in neuroleptic-induced, treatment-resistant tardive dyskinesia. Pharmacogenet. Genomics18(4),317–323 (2008).• Only genome-wide association performed on TD to date
  Medline CASGoogle Scholar
• 137  Risch N, Merikangas K: The future of genetic studies of complex human diseases. Science273,1516–1517 (1996).
  Medline CASGoogle Scholar
• 138  Emahazion T, Feuk L, Jobs M et al.: SNP association studies in Alzheimer’s disease highlight problems for complex disease analysis. Trends Genet.17,407–413 (2001).
  Medline CASGoogle Scholar
• 139  Sanders AR, Gejman PV: Influential ideas and experimental progress in schizophrenia genetics research. JAMA285,2831–2833 (2001).
  Medline CASGoogle Scholar
• 140  Jablensky A: Subtyping schizophrenia: implications for genetic research. Mol. Psychiatry11,815–836 (2006).
  Medline CASGoogle Scholar
• 141  Marsden CD, Tarsy D, Baldessarini RJ: Spontaneous and drug induced movement disorders in psychotic patients. In: Psychiatric aspects of neurologic disease. Benson BF, Blumer D (Eds). Grune and Stratton, NY, USA, 219–265 (1975).
  Google Scholar
• 142  Owens DGC, Johnstone EC, Frith ED: Spontaneous involuntary disorders of movement: their prevalence, severity, and distribution in chronic schizophrenics with and without treatment with neuroleptics. Arch. Gen. Psychiatry39,452–461 (1982).
  Medline CASGoogle Scholar
• 143  Walsh T, McClellan JM, McCarthy SE et al.: Rare structural variants disrupt multiple genes in neurodevelopmental pathways in schizophrenia. Science320(5875),539–543 (2008).
  Medline CASGoogle Scholar
• 144  Yan J, Noltner K, Feng J et al.: Neurexin 1α structural variants associated with autism. Neurosci. Lett.438(3),368–370 (2008).
  Medline CASGoogle Scholar
• 145  Bacchelli E, Blasi F, Biondolillo M et al.: Screening of nine candidate genes for autism on chromosome 2q reveals rare nonsynonymous variants in the cAMP-GEFII gene. Mol. Psychiatry8(11),916–924 (2003).
  Medline CASGoogle Scholar
• 146  Xu B, Roos JL, Levy S, van Rensburg EJ, Gogos JA, Karayiorgou M: Strong association of de novo copy number mutations with sporadic schizophrenia. Nat. Genet.40,880–885 (2008).
  Medline CASGoogle Scholar
• 147  Sebat J, Lakshmi B, Malhotra D et al.: Strong association of de novo copy number mutations with autism. Science316(5823),445–449 (2007).
  Medline CASGoogle Scholar
• 148  Lander E, Kruglyak L: Genetic dissection of complex traits: guidelines for interpreting and reporting linkage results. Nat. Genet.11241–247 (1995).
  Medline CASGoogle Scholar
• 149  Suraez B, Hampe CL, van Eedewlgh P: Problems replicating linkage claims in psychiatry. In: New genetic approaches to mental disorders. Gershon ES, Cloninger CR (Eds). American Psychiatry Press, Washington DC, USA (1995).
  Google Scholar
• 150  Lowe CE, Cooper JD, Chapman JM et al.: Cost-effective analysis of candidate genes using htSNPs: a staged approach. Genes Immun.5,301–305 (2004).
  Medline CASGoogle Scholar
• 151  Aplenc R, Zhao H, Rebbeck TR, Propert KJ: Group sequential methods and sample size savings in biomarker-disease association studies. Genetics163,1215–1219 (2003).
  Medline CASGoogle Scholar
• 152  Satagopan JM, Elston RC: Optimal two-stage genotyping in population-based association studies. Genet. Epidemiol.25,149–157 (2003).
  MedlineGoogle Scholar
• 153  Schooler NR, Kane JM: Research diagnoses for tardive dyskinesia. Arch. Gen. Psychiatry39(4),486–487 (1982).
  Medline CASGoogle Scholar
• 154  Guy W (Ed.).: Early Clinical Drug Evaluation Unit B Assessment Manual. US Department of Health and Human Services, National Institute of Mental Health (NIMH), MD, USA (1976).
  Google Scholar
• 155  Simpson GH, Angus GSW: A rating scale for extrapyramidal side effects. Acta Psychiatr. Scand.212,11–19 (1970).
  CASGoogle Scholar
• 156  Ennis S, Goverdhan S, Cree A, Hoh J, Collins A, Lotery A: Fine-scale linkage disequilibrium mapping of age-related macular degeneration in the complement factor H gene region. Br. J. Ophthalmol.91(7),966–970 (2007).
  MedlineGoogle Scholar
• 157  Gudmundsson J, Sulem P, Manolescu A et al.: Genome-wide association study identifies a second prostate cancer susceptibility variant at 8q24. Nat. Genet.39(5),631–637 (2007).
  Medline CASGoogle Scholar
• 158  Libioulle C, Louis E, Hansoul S et al.: Novel Crohn disease locus identified by genome-wide association maps to a gene desert on 5p13.1 and modulates expression of PTGER4. PLoS Genet.3(4),E58 (2007).
  MedlineGoogle Scholar
• 159  Saxena R, Voight BF, Lyssenko V et al.: Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science316(5829),1331–1336 (2007).
  Medline CASGoogle Scholar
• 160  Lencz T, Morgan TV, Athanasiou M et al.: Converging evidence for a pseudoautosomal cytokine receptor gene locus in schizophrenia. Mol. Psychiatry12(6),572–580 (2007).
  Medline CASGoogle Scholar
• 161  Kirov G, Zaharieva I, Georgieva L et al.: A genome-wide association study in 574 schizophrenia trios using DNA pooling. Mol. Psychiatry (2008) (Epub ahead of print).
  Google Scholar
• 162  Shifman S, Johannesson M, Bronstein M et al.: Genome-wide association identifies a common variant in the reelin gene that increases the risk of schizophrenia only in women. PLoS Genet.4(2),E28 (2008).
  MedlineGoogle Scholar
• 163  Petronis A: The origin of schizophrenia: genetic thesis, epigenetic antithesis, and resolving synthesis. Biol. Psychiatry.55(10),965–970 (2004).
  Medline CASGoogle Scholar
• 164  Petronis A: Epigenetics and twins: three variations on the theme. Trends Genet.22(7),347–350 (2006).
  Medline CASGoogle Scholar
• 165  Costa E, Grayson DR, Guidotti A: Epigenetic downregulation of GABAergic function in schizophrenia: potential for pharmacological intervention? Mol. Interv.3(4),220–229 (2003).
  Medline CASGoogle Scholar
• 166  Abdolmaleky HM, Thiagalingam S, Wilcox M: Genetics and epigenetics in major psychiatric disorders: dilemmas, achievements, applications, and future scope. Am. J. Pharmacogenomics5(3),149–160 (2005).
  Medline CASGoogle Scholar
• 167  Winterer G, Hermann WM: Valproate and the symptomatic treatment of schizophrenia spectrum patients. Pharmacopsychiatry33(5),182–188 (2000).
  Medline CASGoogle Scholar
• 168  Gimelbrant A, Hutchinson JN, Thompson BR, Chess A: Widespread monoallelic expression on human autosomes. Science318(5853),1136–1140 (2007).
  Medline CASGoogle Scholar
• 169  Bray NJ, Buckland PR, Williams NM et al.: A haplotype implicated in schizophrenia susceptibility is associated with reduced COMT expression in human brain. Am. J. Hum. Genet.73(1),152–161 (2003).
  Medline CASGoogle Scholar
• 170  Zhu G, Lipsky RH, Xu K et al.: Differential expression of human COMT alleles in brain and lymphoblasts detected by RT-coupled 5’ nuclease assay. Psychopharmacology (Berl.)177(1–2),178–184 (2004).
  Medline CASGoogle Scholar
• 171  Tiwari AK, Deshpande SN, Rao AR et al.: Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: III. Lack of association of CYP3A4 and CYP2D6 gene polymorphisms. Schizophr. Res.75(1),21–26 (2005).
  MedlineGoogle Scholar
• 172  Tiwari AK, Deshpande SN, Rao AR et al.: Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J.5(1),60–69 (2005).
  Medline CASGoogle Scholar
• 173  Thelma BK, Tiwari AK, Deshpande SN, Lerer B, Nimgaonkar VL: Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: role of oxidative stress pathway genes. Schizophr. Res.92(1–3),278–279 (2007).
  Medline CASGoogle Scholar
• 174  Ramachandran S, Deshpande O, Roseman CC, Rosenberg NA, Feldman MW, Cavalli-Sforza LL: Support from the relationship of genetic and geographic distance in human populations for a serial founder effect originating in Africa. Proc. Natl Acad. Sci. USA102(44),15942–15947 (2005).
  Medline CASGoogle Scholar
• 175  Prugnolle F, Manica A, Balloux F: Geography predicts neutral genetic diversity of human populations. Curr. Biol.15(5),R159–R160 (2005).
  Medline CASGoogle Scholar
• 176  Liu H, Prugnolle F, Manica A, Balloux F: A geographically explicit genetic model of worldwide human-settlement history. Am. J. Hum. Genet.79(2),230–237 (2006).
  Medline CASGoogle Scholar
• 177  Balaresque PL, Ballereau SJ, Jobling MA: Challenges in human genetic diversity: demographic history and adaptation. Hum. Mol. Genet.16(Spec No. 2),R134–R139 (2007).
  Medline CASGoogle Scholar
• 178  Linz B, Balloux F, Moodley Y et al.: An African origin for the intimate association between humans and Helicobacter pylori.Nature445(7130),915–918 (2007).
  MedlineGoogle Scholar
• 179  Prasad P, Thelma BK: Normative genetic profiles of RAAS pathway gene polymorphisms in North Indian and South Indian populations. Hum. Biol.79(2),241–254 (2007).
  MedlineGoogle Scholar
• 180  Tiwari AK, Punia S, Juyal RC, Thelma BK: Genetic profiling of genes from the oxidative stress pathway among North and South Indians. Human Biology80(2),161–179 (2008).
  Medline CASGoogle Scholar
• 181  Gary R: Tardive dyskinesia: eliminated, forgotten, or overshadowed? Curr. Opin. Psychiatry20,131–137 (2007).
  MedlineGoogle Scholar
• 182  Ascher-Svanum H, Zhu B, Faries D, Peng X, Kinon B, Tohen M: Tardive dyskinesia and the 3- year course of schizophrenia: results from a large, prospective, naturalistic study. J. Clin. Psychiatry24,E1–E9 (2008).
  Google Scholar
• 183  Ohmori O, Suzuki T, Kojima H et al.: Tardive dyskinesia and debrisoquine 4-hydroxylase (CYP2D6) genotype in Japanese schizophrenics. Schizophr. Res.32(2),107–113 (1998).
  Medline CASGoogle Scholar
• 184  Kapitany T, Meszaros K, Lenzinger E et al.: Genetic polymorphisms for drug metabolism (CYP2D6) and tardive dyskinesia in schizophrenia. Schizophr. Res.32(2),101–106 (1998).
  Medline CASGoogle Scholar
• 185  Lam LC, Garcia-Barcelo MM, Ungvari GS et al.: Cytochrome P450 2D6 genotyping and association with tardive dyskinesia in Chinese schizophrenic patients. Pharmacopsychiatry34,238–241 (2001).
  Medline CASGoogle Scholar
• 186  Ellingrod VL, Schultz SK, Arndt S: Abnormal movements and tardive dyskinesia in smokers and nonsmokers with schizophrenia genotyped for cytochrome P450 2D6. Pharmacotherapy22(11),1416–1419 (2002).
  MedlineGoogle Scholar
• 187  Schillevoort I, de Boer A, van der Weide J et al.: Antipsychotic-induced extrapyramidal syndromes and cytochrome P450 2D6 genotype: a case-control study. Pharmacogenetics12(3),235–240 (2002).
  Medline CASGoogle Scholar
• 188  Nikoloff D, Shim JC, Fairchild M et al.: Association between CYP2D6 genotype and tardive dyskinesia in Korean schizophrenics. Pharmacogenomics J.2(6),400–407 (2002).
  Medline CASGoogle Scholar
• 189  Inada T, Senoo H, Iijima Y, Yamauchi T, Yagi G: Cytochrome P450 II D6 gene polymorphisms and the neuroleptic-induced extrapyramidal symptoms in Japanese schizophrenic patients. Psychiatr. Genet.13(3),163–168 (2003).
  MedlineGoogle Scholar
• 190  Liou YJ, Wang YC, Bai YM et al.: Cytochrome P-450 2D6*10 C188T polymorphism is associated with antipsychotic-induced persistent tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology49(4),167–173 (2004).
  Medline CASGoogle Scholar
• 191  Fu Y, Fan CH, Deng HH et al.: Association of CYP2D6 and CYP1A2 gene polymorphism with tardive dyskinesia in Chinese schizophrenic patients. Acta Pharmacol. Sin.27(3),328–332 (2006).
  Medline CASGoogle Scholar
• 192  Basile VS, Ozdemir V, Masellis M et al.: A functional polymorphism of the cytochrome P450 1A2(CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol. Psychiatry5,410–417 (2000).
  Medline CASGoogle Scholar
• 193  Hori H, Ohmori O, Shinkai T, Kojima H, Nakamura J: Association between three functional polymorphisms of dopamine D2 receptor gene and tardive dyskinesia in schizophrenia. Am. J. Med. Genet.105(8),774–778 (2001).
  Medline CASGoogle Scholar
• 194  Mo GH, Lai IC, Wang YC et al.: Support for an association of the C939T polymorphism in the human DRD2 gene with tardive dyskinesia in schizophrenia. Schizophr. Res.97(1–3),302–304 (2007).
  MedlineGoogle Scholar
• 195  Zai CC, Hwang RW, De Luca V et al.: Association study of tardive dyskinesia and twelve DRD2 polymorphisms in schizophrenia patients. Int. J. Neuropsychopharmacol.10(5),639–651 (2007).
  Medline CASGoogle Scholar
• 196  Steen VM, Lovlie R, MacEwan T, McCreadie RG: Dopamine D3-receptor gene variant and susceptibility to tardive dyskinesia in schizophrenic patients. Mol. Psychiatry (2),139–145 (1997).
  MedlineGoogle Scholar
• 197  Segman RH, Neeman T, Heresco-Levy U et al.: Genotypic association between the dopamine D3 receptor gene and tardive dyskinesia in chronic schizophrenia. Mol. Psychiatry4,247–253 (1999).
  Medline CASGoogle Scholar
• 198  Liao DL, Yeh YC, Chen HM, Chen H, Hong CJ, Tsai SJ: Association between the Ser9Gly polymorphism of the dopamine D3 receptor gene and tardive dyskinesia in Chinese schizophrenic patients. Neuropsychobiology44,95–98 (2001).
  Medline CASGoogle Scholar
• 199  Woo SI, Kim JW, Rha E et al.: Association of the Ser9Gly polymorphism in the dopamine D3 receptor gene with tardive dyskinesia in Korean schizophrenics. Psychiatry Clin. Neurosci.56(4),469–474 (2002).
  Medline CASGoogle Scholar
• 200  Lerer B, Segman RH, Fangerau H et al.: Pharmacogenetics of tardive dyskinesia: combined analysis of 780 patients supports association with dopamine D3 receptor gene Ser9Gly polymorphism. Neuropsychopharmacology27(1),105–119 (2002).
  Medline CASGoogle Scholar
• 201  de Leon J, Susce MT, Pan RM, Koch WH, Wedlund PJ: Polymorphic variations in GSTM1, GSTT1, PgP, CYP2D6, CYP3A5, and dopamine D2 and D3 receptors and their association with tardive dyskinesia in severe mental illness. J. Clin. Psychopharmacol.25(5),448–456 (2005).
  Medline CASGoogle Scholar
• 202  Bakker PR, van Harten PN, van Os J: Antipsychotic-induced tardive dyskinesia and the Ser9Gly polymorphism in the DRD3 gene: a meta analysis. Schizophr. Res.83(2–3),185–192 (2006).
  MedlineGoogle Scholar
• 203  Lattuada E, Cavallaro R, Serretti A, Lorenzi C, Smeraldi E: Tardive dyskinesia and DRD2, DRD3, DRD4, 5-HT2A variants in schizophrenia: an association study with repeated assessment. Int. J. Neuropsychopharmacol.7(4),489–493 (2004).
  Medline CASGoogle Scholar
• 204  Tan EC, Chong SA, Mahendran R, Dong F, Tan CH: Susceptibility to neuroleptic-induced tardive dyskinesia and the T102C polymorphism inthe serotonin type 2A receptor. Biol. Psychiatry.144,147–150 (2001).
  Google Scholar
• 205  Lerer B, Segman RH, Tan EC et al.: Combined analysis of 635 patients confirms an age-related association of the serotonin 2A receptor gene with tardive dyskinesia and specificity for the non-orofacial subtype. Int. J. Neuropsychopharmacol.8,411–425 (2005).
  Medline CASGoogle Scholar
• 206  Boke O, Gunes S, Kara N et al.: Association of serotonin 2A receptor and lack of association of CYP1A2 gene polymorphism with tardive dyskinesia in a Turkish population. DNA Cell Biol.26(8),527–531 (2007).
  Medline CASGoogle Scholar
• 207  Segman RH, Heresco-Levy U, Finkel B et al.: Association between the serotonin 2C receptor gene and tardive dyskinesia in chronic schizophrenia: additive contribution of 5-HT2Cser and DRD3gly alleles to susceptibility. Psychopharmacology (Berl.)152(4),408–413 (2000).
  Medline CASGoogle Scholar
• 208  Zhang ZJ, Zhang XB, Sha WW, Zhang XB, Reynolds GP: Association of a polymorphism in the promoter region of the serotonin 5-HT2C receptor gene with tardive dyskinesia in patients with schizophrenia. Mol. Psychiatry7(7),670–671 (2002).
  Medline CASGoogle Scholar
• 209  Ohmori O, Shinkai T, Hori H, Kojima H, Nakamura J: Polymorphisms of µ and δ opioid receptor genes and tardive dyskinesia in patients with schizophrenia. Schizophr. Res.52(1–2),137–138 (2001).
  Medline CASGoogle Scholar
• 210  Lai IC, Liao DL, Bai YM et al.: Association study of the estrogen receptor polymorphisms with tardive dyskinesia in schizophrenia. Neuropsychobiology46(4),173–175 (2002).
  Medline CASGoogle Scholar
• 211  Pae CU, Yu HS, Kim JJ et al.: Quinone oxidoreductase (NQO1) gene polymorphism (609C/T) may be associated with tardive dyskinesia, but not with the development of schizophrenia. Int. J. Neuropsychopharmacol.7(4),495–500 (2004).
  Medline CASGoogle Scholar
• 212  Liou YJ, Lai IC, Lin MW et al.: Haplotype analysis of endothelial nitric oxide synthase (NOS3) genetic variants and tardive dyskinesia in patients with schizophrenia. Pharmacogenet. Genomics16(3),151–157 (2006).
  Medline CASGoogle Scholar
• 301  AmpliChip^® Home www.amplichip.us/
  Google Scholar
• 302  Roche Amplichip background information www.roche.com/med_backgr-ampli.htm
  Google Scholar
• 303  Illumina whole-genome genotyping: human-1 genotyping beadchip www.illumina.com/pages.ilmn?ID=151
  Google Scholar
• 304  International HapMap project www.hapmap.org
  Google Scholar